You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

131I-omburtamab

Showing 1 - 25 of 3,386
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CNS/Leptomeningeal Tumors Trial in New York (131I-omburtamab)

Available
  • Central Nervous System/Leptomeningeal Neoplasms
  • 131I-omburtamab
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 15, 2022

DIPG Trial (131I-Omburtamab, Convention Enhanced Delivery)

Not yet recruiting
  • DIPG
  • 131I-Omburtamab
  • Convention Enhanced Delivery
  • (no location specified)
Feb 7, 2022

Neuroblastoma, CNS Metastases, Leptomeningeal Metastases Trial in Worldwide (131I-omburtamab)

Recruiting
  • Neuroblastoma
  • +2 more
  • 131I-omburtamab
  • Los Angeles, California
  • +11 more
Dec 17, 2021

Leptomeningeal Metastasis, Solid Tumor, Adult Trial in United Kingdom, United States (radiolabeled DPTA-omburtamab)

Withdrawn
  • Leptomeningeal Metastasis
  • Solid Tumor, Adult
  • radiolabeled DPTA-omburtamab
  • Los Angeles, California
  • +7 more
Jul 12, 2022

Medulloblastoma, Childhood Trial in Worldwide (177Lu-DTPA-omburtamab)

Terminated
  • Medulloblastoma, Childhood
  • Rochester, Minnesota
  • +9 more
Aug 15, 2022

HER2-positive Breast Cancer Trial in Shanghai (68Ga/131I-SGMIB-5F7)

Not yet recruiting
  • HER2-positive Breast Cancer
  • 68Ga/131I-SGMIB-5F7
  • Shanghai, China
    Huashan Hospital
Aug 1, 2023

Relapsed Neuroblastoma, Metastatic Pheochromocytoma Trial in Dallas (131 I-Metaiodobenzylguanidine, Potassium Iodide, G-csf)

No longer available
  • Relapsed Neuroblastoma
  • Metastatic Pheochromocytoma
  • 131 I-Metaiodobenzylguanidine
  • +2 more
  • Dallas, Texas
    The University of Texas Southwestern Medical Center
Apr 13, 2022

Melanoma Trial in Clermont-Ferrand ([131I]ICF01012 (therapeutic dose level 1), [131I]ICF01012 (therapeutic dose level 2),

Recruiting
  • Melanoma
  • [131I]ICF01012 (therapeutic dose level 1)
  • +3 more
  • Clermont-Ferrand, France
  • +1 more
Jan 27, 2022

Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme Trial (131I-IPA)

Not yet recruiting
  • Neoplastic Disease
  • +2 more
  • (no location specified)
Jul 6, 2022

Neuroblastoma Trial in United States (131I-MIBG, Dinutuximab, Vorinostat)

Recruiting
  • Neuroblastoma
  • 131I-MIBG
  • +4 more
  • Los Angeles, California
  • +11 more
Jan 30, 2023

Neuroblastoma, Childhood Metastatic Pheochromocytoma Trial in Philadelphia (131 I-Metaiodobenzylguanidine (131 I-MIBG), 131

Available
  • Neuroblastoma
  • Childhood Metastatic Pheochromocytoma
  • 131 I-Metaiodobenzylguanidine (131 I-MIBG)
  • 131 I-MIBG
  • Philadelphia, Pennsylvania
    The Children's Hospital of Philadelphia
Jul 11, 2022

Neuroblastoma Trial in Canada, United States (131I-MIBG, Vincristine, Irinotecan)

Completed
Has Results
  • Neuroblastoma
  • 131I-MIBG
  • +3 more
  • Los Angeles, California
  • +13 more
May 16, 2022

Neuroblastoma, Pheochromocytoma Trial in New Hyde Park (131-I-meta-iodobenzylguanidine)

Available
  • Neuroblastoma
  • Pheochromocytoma
  • New Hyde Park, New York
    Cohen Children's Medical Center
Apr 4, 2022

Thyroid Cancer Trial in Bialystok (metformin, Radioactive iodine (I-131))

Not yet recruiting
  • Thyroid Cancer
  • Bialystok, Poland
    Department of Endocrinology, Diabetology and Internal Medicine,
Jul 26, 2022

Colorectal Tumors Trial in Heidelberg (Capecitabine, 131I-huA33 (131-Iodine on humanised mAb A33))

Completed
Has Results
  • Colorectal Neoplasms
  • Capecitabine
  • 131I-huA33 (131-Iodine on humanised monoclonal antibody A33)
  • Heidelberg, Victoria, Australia
    Ludwig Institute Oncology Unit and Tumor Targeting Program, Aust
Jan 11, 2022

Relapsed Neuroblastoma, Metastatic Pheochromocytoma Trial in Minneapolis (131 I-Metaiodobenzylguanidine (131I-MIBG), Potassium

Recruiting
  • Relapsed Neuroblastoma
  • Metastatic Pheochromocytoma
  • 131 I-Metaiodobenzylguanidine (131I-MIBG)
  • +3 more
  • Minneapolis, Minnesota
    University of Minnesota Masonic Cancer Center
Jan 20, 2022

Kidney Cancer Trial in New York (Iodine-131 radiolabeled chimeric mAb G250 (131I-cG250))

Completed
Has Results
  • Kidney Cancer
  • Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Glioblastoma Multiforme Trial in Australia, Austria, Netherlands (4-L-[131I]iodo-phenylalanine (131I-IPA))

Active, not recruiting
  • Glioblastoma Multiforme
  • 4-L-[131I]iodo-phenylalanine (131I-IPA)
  • Gateshead, New South Wales, Australia
  • +4 more
Nov 25, 2021

Locally Advanced Solid Tumors, Metastatic Solid Tumors Trial in Edmonton ([131]I-IAZA)

Withdrawn
  • Locally Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Jul 7, 2022

Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Worldwide (Iopofosine I 131 single dose,

Recruiting
  • Waldenstrom Macroglobulinemia
  • +8 more
  • Iopofosine I 131 single dose
  • +2 more
  • Redlands, California
  • +42 more
Dec 30, 2022

Neuroblastoma, Neuroectodermal Tumors, Tumors Trial in United States (131I-MIBG, 131-MIBG + Vorinostat)

Recruiting
  • Neuroblastoma
  • +2 more
  • San Francisco, California
  • +15 more
Jan 7, 2022

Peritoneal Cancer Trial in New York (131 I-8H9)

Active, not recruiting
  • Peritoneal Cancer
  • 131 I-8H9
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 7, 2022

Renal Tracer Elimination in Thyroid Cancer Patients Treated With

Completed
  • Thyroid Carcinoma
    • Jena, Thüringen, Germany
      University Hospital Jena
    Dec 15, 2022

    Neuroendocrine Tumors Trial in São Paulo (MIBG-I131)

    Withdrawn
    • Neuroendocrine Tumors
    • MIBG-I131
    • São Paulo, SP, Brazil
      AC Camargo Cancer Center
    May 13, 2022

    Multiple Myeloma Trial in Ann Arbor (Iodine I 131 Tositumomab)

    Active, not recruiting
    Has Results
    • Multiple Myeloma
    • Iodine I 131 Tositumomab
    • Ann Arbor, Michigan
      University of Michigan
    Mar 16, 2022